Clinical trials: Buprenorphine Dependence
Opioid-Related Disorders
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
Buprenorphine is a drug that may be helpful in treating opioid dependent individuals who were previously maintained on methadone.
- Trial name
- NCT00000243
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Dependency
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs.
- Trial name
- NCT01114308
- Testing
- Probuphine (buprenorphine implant), Buprenorphine
- Where
- 20 sites in United States
- Volunteers
- 287 people
- Sponsor
- Titan Pharmaceuticals
Heroin Dependence, Opioid-Related Disorders
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective…
- Trial name
- NCT00000326
- Testing
- Heroin Dependence
- Where
- United States
- Sponsor
- University of Colorado, Denver
Heroin Dependence
A Stepwise Strategy Utilizing Buprenorphine and Methadone
The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy, where patients are offered buprenorphine as first line treatment, allowed…
- Trial name
- NCT00310934
- Testing
- methadone, buprenorphine / methadone sequence, Relapse prevention
- Where
- Sweden
- Volunteers
- 96 people
- Sponsor
- Karolinska University Hospital
Opioid-use Disorder, Opioid Use, Unspecified
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution…
- Conditions
- Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
- Trial name
- Mother/BabyOUD (NCT03923374)
- Testing
- Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Senthil Sadhasivam
Opioid-use Disorder
Improving Office Based Treatment of Opioid Use Disorder With Technology
The goal of this study is to evaluate whether using a novel drug-device combination to deliver buprenorphine/naloxone (B/N) to patients in office-based treatment for Opioid Use Disorder (OUD) is an effective way to improve…
- Trial name
- NCT03586466
- Testing
- BupreCare, Buprenorphine/naloxone, MEMS
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- MedicaSafe, Inc.
Opioid-use Disorder, Opioid Dependence
SMART Effectiveness Trial
The current study piloted two psychosocial interventions developed to increase buprenorphine-naloxone adherence in individuals with opioid use disorder (OUD).
- Conditions
- Opioid-use Disorder, Opioid Dependence, Treatment Adherence
- Trial name
- NCT04464421
- Testing
- Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Karen Derefinko, PhD
Opioid Dependence
Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder
This study will investigate the mechanisms of cognitive-behavioral response to medications used for relapse prevention in opioid use disorder (opioid addiction, OUD), through investigation of the neural circuits underlying key…
- Trial name
- NCT04454411
- Testing
- Brixadi, Vivitrol
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Opioid-use Disorder, Opioid Dependence
Neuromodulation and Cognitive Training in Opioid Use Disorder
The relapsing nature of opioid use disorder is a major obstacle to successful treatment. About 90% of those entering treatment will relapse within one year.
- Conditions
- Opioid-use Disorder, Opioid Dependence, Opioid Abuse
- Trial name
- NCT03773523
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Opioid Use Disorder
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
This study will evaluate the safety, effectiveness and tolerance of low doses of oral naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection of VIVITROL.
- Trial name
- NCT02537574
- Testing
- NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
- Where
- 20 sites in United States
- Volunteers
- 380 people
- Sponsor
- Alkermes, Inc.
Opioid Dependency, HIV Infections
Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
The purpose of this study is to examine the interactions of buprenorphine-naloxone, a medication used to treat opiate (heroin or prescription narcotic) dependence, and medications used in the treatment of HIV disease including…
- Trial name
- NCT00877591
- Testing
- Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Buprenorphine, HIV
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S.
- Conditions
- Buprenorphine, HIV, Drug Abuse, Drug Addiction
- Trial name
- BELIEVE (NCT00798538)
- Testing
- Services will be provided at one site, Services remain dispersed; i.e., not centralized to one-location or provider.
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Substance Use Disorders, Substance Abuse
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.
- Conditions
- Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
- Trial name
- NCT03762798
- Testing
- The Bridge
- Where
- United States
- Sponsor
- The Cleveland Clinic
Opiate Dependence, Drug Dependence
A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
Post-marketing commitment to the European Medicines Agency to conduct a prospective, controlled study of the transfer from Subutex to Suboxone.
- Trial name
- NCT00605033
- Testing
- Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484, Subutex, Buprenorphine Hydrochloride, SCH 28444
- Volunteers
- 241 people
- Sponsor
- Indivior Inc.
Heroin Dependence, Opioid Use Disorder
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
This research deals with behaviors that are part of opioid dependence. The purpose is to study how stress and medication dose can affect opioid drug use.
- Trial name
- BOS (NCT03015246)
- Testing
- Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wayne State University
Opioid Related Disorder
Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects
This is an open-label study in treatment seeking opioid-dependent subjects for safety, tolerability, pharmacokinetics (PK), efficacy markers, and opioid receptor availability of subcutaneous injections of depot buprenorphine…
- Trial name
- NCT01738503
- Testing
- RBP-6000, Subutex
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Indivior Inc.
Heroin Dependence, Opioid-Related Disorders
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers
- Trial name
- NCT00000330
- Testing
- Opioid-Related Disorders
- Where
- United States
- Sponsor
- University of Colorado, Denver
Opiate Dependence
Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers
The primary objective of this study is to compare the bioavailability of a test formulation of Buprenorphine Naloxone Sublingual (SL) spray to that of a single dose of Suboxone® (buprenorphine and naloxone) sublingual film, under…
- Trial name
- NCT02477267
- Testing
- SL spray, SL film
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- INSYS Therapeutics Inc
Opioid Use Disorder, Medication Adherence
MHealth Incentivized Adherence Plus Patient Navigation
Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which…
- Conditions
- Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependence
- Trial name
- MIAPP (NCT06027814)
- Testing
- Patient Navigation and mHealth (PN+mHealth)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Opioid Dependence
Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects
This is a randomized, double blind, placebo controlled study in opioid dependent subjects. Subjects meeting entry criteria will be treated with multiple doses of B-BNX or B-Placebo, with non-responders rescued within 6 hours.
- Trial name
- NCT01713803
- Testing
- Buprenorphine and naloxone
- Where
- United States
- Sponsor
- BioDelivery Sciences International